Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study

被引：0
|
作者：
Delmas, P
Recker, R
Stakkestad, JA
Chestnut, C
Hoiseth, A
Weichselberger, A
Huss, H
von Stein, T
Schimmer, R
机构：
来源：
OSTEOPOROSIS INTERNATIONAL | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 20 条
  • [1] Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval: Results from a pivotal phase III study in postmenopausal osteoporosis (PMO).
    Recker, R
    Stakkestad, JA
    Weber, T
    Cohen, S
    Delmas, P
    Schimmer, R
    Mahoney, P
    Kilbride, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S134 - S134
  • [2] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    Chesnut, CH
    Skag, A
    Christiansen, C
    Recker, R
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Huss, H
    Gilbride, J
    Schimmer, RC
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1241 - 1249
  • [3] Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study
    Stakkestad, Jacob A.
    Emkey, Ronald
    Neate, Colin
    Chesnut, Charles H.
    BONE, 2008, 42 : S86 - S86
  • [4] Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: Further analyses from a pivotal phase III study
    Emkey, R.
    Chesnut, C. H.
    Schimmer, R. C.
    Neate, C.
    Recker, R. R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S329 - S329
  • [5] Oral daily and intermittent ibandronate normalize bone turnover and significantly reduce vertebral fracture risk: Results from a large phase III study.
    Emkey, R
    Recker, RR
    Stakkestad, JA
    Mahoney, P
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S372 - S372
  • [6] Oral daily and intermittent ibandronate significantly reduce the incidence of new vertebral fractures: Results from a multinational phase III fracture study
    Felsenberg, D
    Lorenc, R
    Hughes, C
    Schimmer, RC
    Wasnich, R
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S71 - S72
  • [7] Upper gastrointestinal safety profile of oral daily and intermittent ibandronate: Results from a large pivotal phase III study
    Delmas, PD
    Skag, A
    Chesnut, CH
    Stakkestad, JA
    Christiansen, C
    Hoiseth, A
    Benevolenskaya, L
    Recker, R
    Leishman, B
    Mahoney, P
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [8] Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study
    Recker R.R.
    Weinstein R.S.
    Chesnut III C.H.
    Schimmer R.C.
    Mahoney P.
    Hughes C.
    Bonvoisin B.
    Meunier P.J.
    Osteoporosis International, 2004, 15 (3) : 231 - 237
  • [9] Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE.
    Recker, RR
    Kendler, DL
    Adami, S
    Hughes, C
    Dumont, E
    Schimmer, RC
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
  • [10] The rigorous fracture diagnosis methodology used in the pivotal phase III study supports the antifracture efficacy of oral daily and intermittent ibandronate
    Felsenberg, D
    Armbrecht, G
    Blenk, T
    Chesnut, CH
    Gardner, J
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S106 - S106
12